Inhibition of HIV-1 Infection by Human α-Defensin-5, a Natural Antimicrobial Peptide Expressed in the Genital and Intestinal Mucosae

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Furci, Lucinda ^a   Tolazzi, Monica ^a   Sironi, Francesca ^a   Vassena, Lia ^a   Lusso, Paolo ^b,c  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF CAGLIARI   (Italy)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA DEFENSIN; ALPHA DEFENSIN 5; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; BINDING COMPETITION; BINDING SITE; CD4 LYMPHOCYTE COUNT; CELL FUSION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; FEMALE GENITAL SYSTEM; HOST RESISTANCE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION CONTROL; INFECTION PREVENTION; INNATE IMMUNITY; INTESTINE MUCOSA; IONIC STRENGTH; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS STRAIN;

ALPHA-DEFENSINS; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; FEMALE; GENE EXPRESSION; GENITALIA; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; INTESTINAL MUCOSA; MALE; MUCOUS MEMBRANE; RECEPTORS, CCR5; RECEPTORS, CXCR4; RECOMBINANT PROTEINS; VIRUS INTERNALIZATION;

BACTERIA (MICROORGANISMS); HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84866906328     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045208     Document Type: Article

References (69)

1. WHO: AIDS Epidemic update 2010. UNAIDS website. Available: http://www.unaids.org/globalreport/. Accessed 2012 August 31.
2. Fauci AS, Johnston MI, Dieffenbach CW, Burton DR, Hammer SM, et al. (2008) HIV vaccine research: the way forward. Science 321: 530-532.
3. Shattock RJ, Haynes BF, Pulendran B, Flores J, Esparza J, (2008) Improving defences at the portal of HIV entry: mucosal and innate immunity. PLoS Med 5: e81.
4. Sodora DL, Gettie A, Miller CJ, Marx PA, (1998) Vaginal transmission of SIV: assessing infectivity and hormonal influences in macaques inoculated with cell-free and cell-associated viral stocks. AIDS Res Human Retrov 14Suppl 1: S119-123.
5. Wawer MJ, Gray RH, Sewankambo NK, Serwadda D, Li X, et al. (2005) Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis 191: 1403-1409.
6. Hickey DK, Patel MV, Fahey JV, Wira CR, (2011) Innate and adaptive immunity at mucosal surfaces of the female reproductive tract: stratification and integration of immune protection against the transmission of sexually transmitted infections. J Reprod Immunol 88: 185-194.
7. Venkataraman N, Cole AL, Svoboda P, Pohl J, Cole AM, (2005) Cationic polypeptides are required for anti-HIV-1 activity of human vaginal fluid. J Immunol 175: 7560-7567.
8. Cole AM, Cole AL, (2008) Antimicrobial Polypeptides are Key Anti-HIV-1 Effector Molecules of Cervicovaginal Host Defense. Am J Reprod Immunol 59: 27-34.
9. Wira CR, Patel MV, Ghosh M, Mukura L, Fahey JV, (2011) Innate immunity in the human female reproductive tract: endocrine regulation of endogenous antimicrobial protection against HIV and other sexually transmitted infections. Am J Reprod Immunol 65: 196-211.
10. Valore EV, Park CH, Igreti SL, Ganz T, (2002) Antimicrobial components of vaginal fluid. Am J Obstet Gynecol 187: 561-568.
11. Levinson P, Choi RY, Cole AL, Hirbod T, Rhedin S, et al. (2012) HIV-Neutralizing Activity of Cationic Polypeptides in Cervicovaginal Secretions of Women in HIV-Serodiscordant Relationships. PLoS One 7: e31996.
12. Levinson P, Kaul R, Kimani J, Ngugi E, Moses S, et al. (2009) Levels of innate immune factors in genital fluids: association of α-defensins and LL-37 with genital infections and increased HIV acquisition. AIDS 23: 309-317.
13. Hill CP, Yee J, Selsted ME, Eisenberg D, (1991) Crystal structure of defensin HNP-3, an amphiphilic dimer: mechanisms of membrane permeabilization. Science 251: 1481-1485.
14. Szyk A, Wu Z, Tucker K, Yang D, Lu W, et al. (2006) Crystal structures of human α-defensins HNP4, HD5, and HD6. Protein Sci 15: 2749-2760.
15. Lehrer RI, Lu W, (2012) α-Defensins in human innate immunity. Immunol Rev 245: 84-112.
16. Yang D, Biragyn A, Hoover DM, Lubkowski J, Oppenheim JJ, (2004) Multiple roles of antimicrobial defensins, cathelicidins, and eosinophil-derived neurotoxin in host defense. Annu Rev Immunol 22: 181-215.
17. Klotman ME, Chang TL, (2006) Defensins in innate antiviral immunity. Nat Rev Immunol 6: 447-456.
18. Buck CB, (2008) Defensins' offensive play: exploiting a viral achilles' heel. Cell Host Microbe 3: 3-4.
19. Furci L, Sironi F, Tolazzi M, Vassena L, Lusso P, (2007) α-defensins block the early steps of HIV-1 infection: interference with the binding of gp120 to CD4. Blood 109: 2928-2935.
20. Seidel A, Ye Y, de Armas LR, Soto M, Yarosh W, et al. (2010) Cyclic and acyclic defensins inhibit human immunodeficiency virus type-1 replication by different mechanisms. PLoS One 5: e9737.
21. Demirkhanyan LH, Marin M, Padilla-Parra S, Zhan C, Miyauchi K, et al. (2012) Multifaceted mechanisms of HIV-1 entry inhibition by human α-defensin. J Biol Chem 287: 28821-28831.
22. Svinarich DM, Wolf NA, Gomez R, Gonik B, Romero R, (1997) Detection of human defensin 5 in reproductive tissues. Am J Obstet Gynecol 176: 470-475.
23. Quayle AJ, Porter EM, Nussbaum AA, Wang YM, Brabec C, et al. (1998) Gene expression, immunolocalization, and secretion of human defensin-5 in human female reproductive tract. Am J Pathol 152: 1247-1258.
24. Buck CB, Day PM, Thompson CD, Lubkowski J, Lu W, et al. (2006) Human α-defensins block papillomavirus infection. Proc Natl Acad Sci U S A 103: 1516-1521.
25. Dugan AS, Maginnis MS, Jordan JA, Gasparovic ML, Manley K, et al. (2008) Human α-Defensins Inhibit BK Virus Infection by Aggregating Virions and Blocking Binding to Host Cells. J Biol Chem 283: 31125-31132.
26. Smith JG, Silvestry M, Lindert S, Lu W, Nemerow GR, et al. (2010) Insight into the mechanisms of adenovirus capsid disassembly from studies of defensin neutralization. PLoS Pathog 6: e1000959.
27. Klotman ME, Rapista A, Teleshova N, Micsenyi A, Jarvis GA, et al. (2008) Neisseria gonorrhoeae-induced human defensins 5 and 6 increase HIV infectivity: role in enhanced transmission. J Immunol 180: 6176-6185.
28. Rapista A, Ding J, Benito B, Lo YT, Neiditch MB, et al. (2011) Human defensins 5 and 6 enhance HIV-1 infectivity through promoting HIV attachment. Retrovirology 8: 45.
29. Smith JG, Nemerow GR, (2008) Mechanism of adenovirus neutralization by Human α-defensins. Cell Host Microbe 3: 11-19.
30. Wang W, Owen SM, Rudolph DL, Cole AM, Hong T, et al. (2004) Activity of α- and θ-defensins against primary isolates of HIV-1. J Immunol 173: 515-520.
31. Yahi N, Fantini J, Baghdiguian S, Chermann JC, (1991) Human T-lymphoblastoid cells selected for growth in serum-free medium provide new tools for study of HIV replication and cytopathogenicity. J Virol Methods 34: 193-207.
32. O'Doherty U, Swiggard WJ, Malim MH, (2000) Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding. J Virol 74: 10074-10080.
33. Mandel ID (1972) Mucosal secretions: chemico-physical analysis. In: C.V. Mosby Co. Saliva. 242-251.
34. Porter EM, van Dam E, Valore EV, Ganz T, (1997) Broad-spectrum antimicrobial activity of human intestinal defensin 5. Infect Immun 65: 2396-2401.
35. Berger EA, Murphy PM, Farber JM, (1999) Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Ann Rev Immunol 17: 657-700.
36. Lusso P, Cocchi F, Balotta C, Markham PD, Louie A, et al. (1995) Growth of macrophage-tropic and primary human immunodeficiency virus type 1 (HIV-1) isolates in a unique CD4+ T-cell clone (PM1): failure to downregulate CD4 and to interfere with cell-line-tropic HIV-1. J Virol 69: 3712-3720.
37. McKnight A, Wilkinson D, Simmons G, Talbot S, Picard L, et al. (1997) Inhibition of human immunodeficiency virus fusion by a monoclonal antibody to a coreceptor (CXCR4) is both cell type and virus strain dependent. J Virol 71: 1692-1696.
38. Brelot A, Heveker N, Adema K, Hosie MJ, Willett B, et al. (1999) Effect of mutations in the second extracellular loop of CXCR4 on its utilization by human and feline immunodeficiency viruses. J Virol 73: 2576-2586.
39. Baribaud F, Edwards TG, Sharron M, Brelot A, Heveker N, et al. (2001) Antigenically distinct conformations of CXCR4. J Virol 75: 8957-8967.
40. Lehrer RI, (2007) Multispecific myeloid defensins. Curr Opin Hematol 14: 16-21.
41. Hazrati E, Galen B, Lu W, Wang W, Ouyang Y, et al. (2006) Human α- and β-defensins block multiple steps in herpes simplex virus infection. J Immunol 177: 8658-8666.
42. Tanabe H, Ouellette AJ, Cocco MJ, Robinson WE Jr, (2004) Differential effects on human immunodeficiency virus type 1 replication by α-defensins with comparable bactericidal activities. J Virol 78: 11622-11631.
43. de Leeuw E, Burks SR, Li X, Kao JP, Lu W, (2007) Structure-dependent functional properties of human defensin 5. FEBS Lett 581: 515-520.
44. Grigat J, Soruri A, Forssmann U, Riggert J, Zwirner J, (2007) Chemoattraction of macrophages, T lymphocytes, and mast cells is evolutionarily conserved within the human α-defensin family. J Immunol 179: 3958-3965.
45. Porter E, Yang H, Yavagal S, Preza GC, Murillo O, et al. (2005) Distinct defensin profiles in Neisseria gonorrhoeae and Chlamydia trachomatis urethritis reveal novel epithelial cell-neutrophil interactions. Infect Immun 73: 4823-4833.
46. Davis HE, Rosinski M, Morgan JR, Yarmush ML, (2004) Charged polymers modulate retrovirus transduction via membrane charge neutralization and virus aggregation. Biophys J 86: 1234-1242.
47. Lehrer RI, Jung G, Ruchala P, Andre S, Gabius HJ, et al. (2009) Multivalent binding of carbohydrates by the human α-defensin, HD5. J Immunol 183: 480-490.
48. Appay V, Rowland-Jones SL, (2001) RANTES: a versatile and controversial chemokine. Trends Immunol 22: 83-87.
49. Jameson BA, Rao PE, Kong LI, Hahn BH, Shaw GM, et al. (1988) Location and chemical synthesis of a binding site for HIV-1 on the CD4 protein. Science 240: 1335-1339.
50. Cardozo T, Kimura T, Philpott S, Weiser B, Burger H, et al. (2007) Structural basis for coreceptor selectivity by the HIV type 1 V3 loop. AIDS Res Hum Retrov 23: 415-426.
51. Cocchi F, DeVico AL, Garzino-Demo A, Cara A, Gallo RC, et al. (1996) The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection. Nat Med 2: 1244-1247.
52. Quinones-Mateu ME, Lederman MM, Feng Z, Chakraborty B, Weber J, et al. (2003) Human epithelial β-defensins 2 and 3 inhibit HIV-1 replication. AIDS 17: F39-48.
53. Feng Z, Dubyak GR, Lederman MM, Weinberg A, (2006) Cutting edge: human β defensin 3-a novel antagonist of the HIV-1 coreceptor CXCR4. J Immunol 177: 782-786.
54. Zhou N, Fang J, Mukhtar M, Acheampong E, Pomerantz RJ, (2004) Inhibition of HIV-1 fusion with small interfering RNAs targeting the chemokine coreceptor CXCR4. Gene Ther 11: 1703-1712.
55. Anderson J, Akkina R, (2005) HIV-1 resistance conferred by siRNA cosuppression of CXCR4 and CCR5 coreceptors by a bispecific lentiviral vector. AIDS Res Ther 2: 1.
56. Ghosh D, Porter E, Shen B, Lee SK, Wilk D, et al. (2002) Paneth cell trypsin is the processing enzyme for human defensin-5. Nat Immunol 3: 583-590.
57. Chen L, Kwon YD, Zhou T, Wu X, O'Dell S, et al. (2009) Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science 326: 1123-1127.
58. Chang TL, Vargas J Jr, DelPortillo A, Klotman ME, (2005) Dual role of α-defensin-1 in anti-HIV-1 innate immunity. J Clin Invest 115: 765-773.
59. Brenchley JM, Douek DC, (2008) HIV infection and the gastrointestinal immune system. Mucosal Immunol 1: 23-30.
60. Zaragoza MM, Sankaran-Walters S, Canfield DR, Hung JK, Martinez E, et al. (2011) Persistence of gut mucosal innate immune defenses by enteric α-defensin expression in the simian immunodeficiency virus model of AIDS. J Immunol 186: 1589-1597.
61. Lagenaur LA, Sanders-Beer BE, Brichacek B, Pal R, Liu X, et al. (2011) Prevention of vaginal SHIV transmission in macaques by a live recombinant Lactobacillus. Mucosal Immunol 4: 648-657.
62. Kaul R, Rebbapragada A, Hirbod T, Wachihi C, Ball TB, et al. (2008) Genital levels of soluble immune factors with anti-HIV activity may correlate with increased HIV susceptibility. AIDS 22: 2049-2051.
63. Iqbal SM, Kaul R, (2008) Mucosal innate immunity as a determinant of HIV susceptibility. Am J Reprod Immunol 59: 44-54.
64. Eade CR, Wood MP, Cole AM, (2012) Mechanisms and modifications of naturally occurring host defense peptides for anti-HIV microbicide development. Current HIV research 10: 61-72.
65. Lusso P, Earl PL, Sironi F, Santoro F, Ripamonti C, et al. (2005) Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains. J Virol 79: 6957-6968.
66. Scarlatti G, Tresoldi E, Bjorndal A, Fredriksson R, Colognesi C, et al. (1997) In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nat Med 3: 1259-1265.
67. Zhou Y, Zhang H, Siliciano JD, Siliciano RF, (2005) Kinetics of human immunodeficiency virus type 1 decay following entry into resting CD4+ T cells. J Virol 79: 2199-2210.
68. Moore JP, McKeating JA, Weiss RA, Sattentau QJ, (1990) Dissociation of gp120 from HIV-1 virions induced by soluble CD4. Science 250: 1139-1142.
69. Nussbaum O, Broder CC, Berger EA, (1994) Fusogenic mechanisms of enveloped-virus glycoproteins analyzed by a novel recombinant vaccinia virus-based assay quantitating cell fusion- dependent reporter gene activation. J Virol 68: 5411-5422.